UroGen Pharma Announces Data Of Phase 2b Of Bladder Cancer Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 21 2025
0mins
Should l Buy URGN?
Source: NASDAQ.COM
Study Results: UroGen Pharma announced positive results from a five-year extension study of the Phase 2b OPTIMA II trial for ZUSDURI, showing that 25 out of 41 patients maintained a complete response at 12 months, with a median duration of response of 3.5 years among those in long-term follow-up.
Clinical Implications: The Chief Medical Officer highlighted ZUSDURI as a non-surgical treatment option for recurrent bladder cancer patients, providing an alternative that aligns with individual patient needs and preferences.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy URGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on URGN
Wall Street analysts forecast URGN stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 19.910
Low
31.00
Averages
40.25
High
55.00
Current: 19.910
Low
31.00
Averages
40.25
High
55.00
About URGN
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UroGen Pharma Reports 2025 Financial Highlights
- Significant Revenue Growth: UroGen Pharma reported fourth-quarter 2025 revenue of $37.8 million, a 53.3% increase from $24.6 million in the same quarter of 2024, indicating strong market demand following the launch of new products and enhancing future revenue expectations.
- Narrowed Net Loss: The net loss for the fourth quarter of 2025 was $26.4 million, or $0.54 per share, significantly improved from a net loss of $37.5 million, or $0.80 per share in the same quarter of 2024, reflecting effective cost control and revenue growth.
- Successful Launch of ZUSDURI: ZUSDURI, the first FDA-approved therapy for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, generated $15.8 million in net sales during 2025, with expectations for broader patient access supported by a permanent J Code effective January 1, 2026.
- Refinancing Agreement Restructured: UroGen secured up to $250 million in senior secured debt through a refinancing agreement with Pharmakon Advisors, with the first tranche of $200 million used to refinance an existing loan, alleviating financial pressure and providing funding for future R&D.
See More
UroGen Pharma Q4 2025 Earnings Call Highlights
- ZUSDURI Commercial Launch: UroGen Pharma's ZUSDURI generated $15.8 million in revenue for 2025, reflecting a strong market entry in non-muscle invasive bladder cancer, with potential peak revenue exceeding $1 billion anticipated in the future.
- Enhanced Financial Flexibility: The company secured a new $250 million loan agreement with Pharmakon Advisors, significantly improving its financial position to support ZUSDURI's market rollout and R&D activities.
- Significant Sales Growth: Total revenues reached $109.8 million in 2025, a 21% year-over-year increase driven primarily by the launch of ZUSDURI and growth in JELMYTO sales, indicating robust market performance.
- Cautious Future Outlook: While management expressed optimism about early indicators for ZUSDURI, no formal sales guidance for 2026 was provided, emphasizing the need to observe steady-state demand following the J-code implementation.
See More
UroGen (URGN) Q4 2025 Earnings Call Transcript
See More
UroGen Pharma Q4 Earnings Miss Expectations
- Earnings Performance: UroGen Pharma reported a Q4 GAAP EPS of -$0.54, missing expectations by $0.03, indicating ongoing challenges in profitability that could undermine investor confidence.
- Revenue Growth: Despite a 54% year-over-year revenue increase to $37.84 million, the figure fell short of expectations by $2.08 million, reflecting intensified market competition and potential shortcomings in sales strategies that may impact future market share.
- Market Reaction: The earnings miss may put downward pressure on UroGen's stock price, prompting investors to closely monitor the company's strategic adjustments and efforts to improve profitability moving forward.
- Analyst Ratings: According to Seeking Alpha's Quant Rating, UroGen's financial performance and market outlook could influence analysts' future rating adjustments, necessitating a cautious risk assessment by investors.
See More
UroGen's ZUSDURI Shows Efficacy at ASCO-GU 2026
- Efficacy Analysis: In the ENVISION trial, ZUSDURI (mitomycin) demonstrated durable complete response rates across EORTC recurrence score groups, achieving 83.9% in low-risk (1-4), 81.2% in intermediate-risk (5-9), and 60.0% in high-risk (10-17) patients, indicating its effectiveness across varying risk profiles.
- Long-Term Outcomes: Among patients treated with ZUSDURI, the majority remained recurrence-free at 24 months, with event-free survival rates of 67.4% for low-risk, 73.7% for intermediate-risk, and 66.7% for high-risk groups, showcasing the drug's long-term efficacy and clinical significance.
- Clinical Implications: These results highlight ZUSDURI's ability to achieve significant complete responses even in high-recurrence-risk patients, addressing a critical treatment gap for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, thus holding substantial clinical promise.
- Future Research: The ENVISION trial will continue to monitor patients for recurrence and progression for up to five years, further validating ZUSDURI's efficacy and safety, and promoting its clinical application.
See More
Wildcat Capital Exits UroGen Pharma Position, Liquidating Approximately $6.79 Million
- Complete Exit: Wildcat Capital Management disclosed in an SEC filing on November 13 that it sold all 495,606 shares of UroGen Pharma, liquidating approximately $6.79 million, which reduces its investment stake from 4% to 0%.
- Stock Performance: UroGen Pharma's shares have surged 113% over the past year, currently priced at $23.52, significantly outperforming the overall market, which has only risen 15%, indicating strong performance in the biotech sector.
- Investment Background: Founded in 2011 as the single-family office of billionaire investor David Bonderman, Wildcat has historically favored concentrated investments over short-term trading, making this exit appear more like disciplined capital recycling rather than a lack of confidence in the company.
- Future Outlook: While UroGen's Jelmyto remains its commercial anchor and the pipeline targets significant unmet needs in urothelial cancers, the volatility in biotech stocks suggests that this exit may signal that investors believe the best returns have already been realized.
See More
UroGen Pharma Reports 2025 Financial Highlights
- Significant Revenue Growth: UroGen Pharma reported fourth-quarter 2025 revenue of $37.8 million, a 53.3% increase from $24.6 million in the same quarter of 2024, indicating strong market demand following the launch of new products and enhancing future revenue expectations.
- Narrowed Net Loss: The net loss for the fourth quarter of 2025 was $26.4 million, or $0.54 per share, significantly improved from a net loss of $37.5 million, or $0.80 per share in the same quarter of 2024, reflecting effective cost control and revenue growth.
- Successful Launch of ZUSDURI: ZUSDURI, the first FDA-approved therapy for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, generated $15.8 million in net sales during 2025, with expectations for broader patient access supported by a permanent J Code effective January 1, 2026.
- Refinancing Agreement Restructured: UroGen secured up to $250 million in senior secured debt through a refinancing agreement with Pharmakon Advisors, with the first tranche of $200 million used to refinance an existing loan, alleviating financial pressure and providing funding for future R&D.
See More
UroGen Pharma Q4 2025 Earnings Call Highlights
- ZUSDURI Commercial Launch: UroGen Pharma's ZUSDURI generated $15.8 million in revenue for 2025, reflecting a strong market entry in non-muscle invasive bladder cancer, with potential peak revenue exceeding $1 billion anticipated in the future.
- Enhanced Financial Flexibility: The company secured a new $250 million loan agreement with Pharmakon Advisors, significantly improving its financial position to support ZUSDURI's market rollout and R&D activities.
- Significant Sales Growth: Total revenues reached $109.8 million in 2025, a 21% year-over-year increase driven primarily by the launch of ZUSDURI and growth in JELMYTO sales, indicating robust market performance.
- Cautious Future Outlook: While management expressed optimism about early indicators for ZUSDURI, no formal sales guidance for 2026 was provided, emphasizing the need to observe steady-state demand following the J-code implementation.
See More
UroGen (URGN) Q4 2025 Earnings Call Transcript
See More
UroGen Pharma Q4 Earnings Miss Expectations
- Earnings Performance: UroGen Pharma reported a Q4 GAAP EPS of -$0.54, missing expectations by $0.03, indicating ongoing challenges in profitability that could undermine investor confidence.
- Revenue Growth: Despite a 54% year-over-year revenue increase to $37.84 million, the figure fell short of expectations by $2.08 million, reflecting intensified market competition and potential shortcomings in sales strategies that may impact future market share.
- Market Reaction: The earnings miss may put downward pressure on UroGen's stock price, prompting investors to closely monitor the company's strategic adjustments and efforts to improve profitability moving forward.
- Analyst Ratings: According to Seeking Alpha's Quant Rating, UroGen's financial performance and market outlook could influence analysts' future rating adjustments, necessitating a cautious risk assessment by investors.
See More
UroGen's ZUSDURI Shows Efficacy at ASCO-GU 2026
- Efficacy Analysis: In the ENVISION trial, ZUSDURI (mitomycin) demonstrated durable complete response rates across EORTC recurrence score groups, achieving 83.9% in low-risk (1-4), 81.2% in intermediate-risk (5-9), and 60.0% in high-risk (10-17) patients, indicating its effectiveness across varying risk profiles.
- Long-Term Outcomes: Among patients treated with ZUSDURI, the majority remained recurrence-free at 24 months, with event-free survival rates of 67.4% for low-risk, 73.7% for intermediate-risk, and 66.7% for high-risk groups, showcasing the drug's long-term efficacy and clinical significance.
- Clinical Implications: These results highlight ZUSDURI's ability to achieve significant complete responses even in high-recurrence-risk patients, addressing a critical treatment gap for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, thus holding substantial clinical promise.
- Future Research: The ENVISION trial will continue to monitor patients for recurrence and progression for up to five years, further validating ZUSDURI's efficacy and safety, and promoting its clinical application.
See More
Wildcat Capital Exits UroGen Pharma Position, Liquidating Approximately $6.79 Million
- Complete Exit: Wildcat Capital Management disclosed in an SEC filing on November 13 that it sold all 495,606 shares of UroGen Pharma, liquidating approximately $6.79 million, which reduces its investment stake from 4% to 0%.
- Stock Performance: UroGen Pharma's shares have surged 113% over the past year, currently priced at $23.52, significantly outperforming the overall market, which has only risen 15%, indicating strong performance in the biotech sector.
- Investment Background: Founded in 2011 as the single-family office of billionaire investor David Bonderman, Wildcat has historically favored concentrated investments over short-term trading, making this exit appear more like disciplined capital recycling rather than a lack of confidence in the company.
- Future Outlook: While UroGen's Jelmyto remains its commercial anchor and the pipeline targets significant unmet needs in urothelial cancers, the volatility in biotech stocks suggests that this exit may signal that investors believe the best returns have already been realized.
See More
